Leroy A. Richardson,

Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2014–21379 Filed 9–8–14; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Georgia Tuberculosis Outbreak Among Homeless

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of award.

SUMMARY: The Centers for Disease Control and Prevention (CDC) located within the United States Department of Health and Human Services (HHS) announces a notice of award to the Georgia Department of Public Health, Tuberculosis (TB) Program. This award will be in the amount of $419,095.00.

The purpose of this award is to halt the further spread of a drug-resistant strain of tuberculosis associated with multiple homeless shelters in Fulton County, Georgia.

DATES: It is expected the notice of award will begin on or about September 3, 2014. The project period will be for one year.

FOR FURTHER INFORMATION CONTACT: Gail Burns-Grant, Division of Tuberculosis Elimination, Field Services and Evaluation Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE., MS E–10, Atlanta, GA 30333; phone: 404–639–5344; email: *GAB2@cdc.gov*.

SUPPLEMENTARY INFORMATION: Currently, the state of Georgia is experiencing a public health emergency in Fulton County where there has been extensive transmission of a drug-resistant strain of tuberculosis (TB) associated with multiple homeless shelters in the county. The Georgia Department of Public Health asked CDC to provide emergency funding for the immediate implementation of CDC recommendations provided as a result of a May 2014 outbreak investigation to prevent further transmission of this drug-resistant strain of tuberculosis and to prevent further deaths associated with this outbreak. Project number is CDC–RFA–PS14–1416.

Dated: September 4, 2014.

Ron A. Otten,

Acting Deputy Associate Director for Science, Centers for Disease Control and Prevention.

[FR Doc. 2014–21455 Filed 9–4–14; 4:15 pm]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2014–N–0001]

Advisory Committee Renewals; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice entitled ''Advisory Committee Renewals'' that appeared in the **Federal Register** of August 25, 2014 (79 FR 50658). The document announced the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs. The table in the document contained several errors. This document corrects those errors.

FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3330, Silver Spring, MD 20993–0002, 301–796–9115.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of Monday, August 25, 2014, in FR Doc. 2014–20017, on page 50659 the table is corrected to read:

Name of committee	Date of expiration
Advisory Committee for Pharmaceutical Science and Clinical Pharmacology	January 22, 2016.
Gastrointestinal Drugs Advisory Committee	March 3, 2016.
Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Reproductive Health Drugs Advisory Committee)	March 23, 2016.
Arthritis Advisory Committee	April 5, 2016.
Pharmacy Compounding Advisory Committee	April 25, 2016.
Anesthetic and Analgesic Drugs Advisory Committee	May 1, 2016.
Blood Products Advisory Committee	May 13, 2016.
Pulmonary-Allergy Drugs Advisory Committee	May 30, 2016.
Drug Safety and Risk Management Advisory Committee	May 31, 2016.
Science Advisory Board to the National Center for Toxicological Research	June 2, 2016.
Peripheral and Central Nervous System Drugs Advisory Committee	June 4, 2016.
Psychopharmacologic Drugs Advisory Committee	June 4, 2016.
Transmissible and Spongiform Encephalopathies Advisory Committee	June 9, 2016.
Science Board to the Food and Drug Administration	June 26, 2016.
Allergenic Products Advisory Committee	July 9, 2016.

Dated: September 3, 2014.

Jill Hartzler Warner,

Associate Commissioner for Special Medical Programs.

[FR Doc. 2014–21369 Filed 9–8–14; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2014–N–1049]

Exploring the Expansion of Conditional Approval to Appropriate Categories of New Animal Drugs

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that it is beginning the exploration process described in a stated performance goal in the Animal Drug User Fee Amendments of 2013 (ADUFA III) goals letter. Consistent with the performance goal, the FDA is inviting comments in regard to the Agency exploring the use of statutory changes to expand the use of conditional approval